Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.
暂无分享,去创建一个
J. Shamash | P. Hutton | O. Ståhl | J. Aparicio | E. Porfiri | K. Dieckmann | J. Beyer | S. Gillessen | A. Fléchon | P. Maroto | D. Klingbiel | U. Basso | B. Laguerre | E. Arriola | A. Lorch | T. Tandstad | C. Chau | M. Wheater | S. Fischer | Kalena Marti | G. Cohn‐Cedermark | B. Škrbinc | A. Flechon
[1] R. Wahlqvist,et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Souchon,et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level , 2016, Journal of Cancer Research and Clinical Oncology.
[3] V. Zagonel,et al. Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. , 2016, Clinical genitourinary cancer.
[4] A. Horwich,et al. Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.
[5] S. Crabb,et al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] T. Powles,et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] I. Christensen,et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. , 2014, European urology.
[8] S. Fosså,et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. Lawton. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group , 2012 .
[10] C. Lawton. Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214) , 2012 .
[11] X. G. Del Muro,et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Trojan,et al. Changes of Stage, Predictive Factors and Adjuvant Treatment Modalities in Seminomatous Testicular Cancer from 1987 to 2007 and Their Impact on the Status of Metastasis, Recurrence-Free and Overall Survival: A Single-Center Analysis , 2011, Urologia Internationalis.
[13] G. Rustin,et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Fosså,et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. , 2011, Journal of the National Cancer Institute.
[15] P. Okunieff,et al. Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .
[16] John D Boice,et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.
[17] G. Rustin,et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.
[18] T. Powles,et al. The changing presentation of germ cell tumours of the testis between 1983 and 2002 , 2005, BJU international.
[19] P. Hall,et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.
[20] Richard Sylvester,et al. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .